These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 15192276)

  • 1. CCR5 promoter polymorphism influences the interferon response of patients with chronic hepatitis C in Japan.
    Konishi I; Horiike N; Hiasa Y; Michitaka K; Onji M
    Intervirology; 2004; 47(2):114-20. PubMed ID: 15192276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C.
    Promrat K; McDermott DH; Gonzalez CM; Kleiner DE; Koziol DE; Lessie M; Merrell M; Soza A; Heller T; Ghany M; Park Y; Alter HJ; Hoofnagle JH; Murphy PM; Liang TJ
    Gastroenterology; 2003 Feb; 124(2):352-60. PubMed ID: 12557141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The CCR5-delta32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source.
    Goulding C; McManus R; Murphy A; MacDonald G; Barrett S; Crowe J; Hegarty J; McKiernan S; Kelleher D
    Gut; 2005 Aug; 54(8):1157-61. PubMed ID: 15863470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of association of some chemokine system polymorphisms with the risks of death and hepatocellular carcinoma occurrence in patients with alcoholic cirrhosis: a prospective study.
    Nahon P; Sutton A; Rufat P; Faisant C; Simon C; Barget N; Trinchet JC; Beaugrand M; Gattegno L; Charnaux N
    Eur J Gastroenterol Hepatol; 2007 May; 19(5):425-31. PubMed ID: 17413295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of CCR5-Delta 32 and CCR2-V64I polymorphisms in a cohort of Spanish HCV patients using real-time polymerase chain reaction and fluorescence resonance energy transfer technologies.
    Ruiz-Ferrer M; Barroso N; Antiñolo G; Aguilar-Reina J
    J Viral Hepat; 2004 Jul; 11(4):319-23. PubMed ID: 15230854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haplotype-tagging RANTES gene variants influence response to antiviral therapy in chronic hepatitis C.
    Wasmuth HE; Werth A; Mueller T; Berg T; Dietrich CG; Geier A; Gartung C; Lorenzen J; Matern S; Lammert F
    Hepatology; 2004 Aug; 40(2):327-34. PubMed ID: 15368437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of genetic polymorphisms with interferon-induced haematologic adverse effects in chronic hepatitis C patients.
    Wada M; Marusawa H; Yamada R; Nasu A; Osaki Y; Kudo M; Nabeshima M; Fukuda Y; Chiba T; Matsuda F
    J Viral Hepat; 2009 Jun; 16(6):388-96. PubMed ID: 19200137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection.
    Hellier S; Frodsham AJ; Hennig BJ; Klenerman P; Knapp S; Ramaley P; Satsangi J; Wright M; Zhang L; Thomas HC; Thursz M; Hill AV
    Hepatology; 2003 Dec; 38(6):1468-76. PubMed ID: 14647058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemokines (RANTES and MCP-1) and chemokine-receptors (CCR2 and CCR5) gene polymorphisms in Alzheimer's and Parkinson's disease.
    Huerta C; Alvarez V; Mata IF; Coto E; Ribacoba R; Martínez C; Blázquez M; Guisasola LM; Salvador C; Lahoz CH; Peña J
    Neurosci Lett; 2004 Nov; 370(2-3):151-4. PubMed ID: 15488313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C.
    Naito M; Matsui A; Inao M; Nagoshi S; Nagano M; Ito N; Egashira T; Hashimoto M; Mishiro S; Mochida S; Fujiwara K
    J Gastroenterol; 2005 Apr; 40(4):381-8. PubMed ID: 15868370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single nucleotide polymorphism of the MxA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection.
    Suzuki F; Arase Y; Suzuki Y; Tsubota A; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Takagi K; Satoh J; Kumada H
    J Viral Hepat; 2004 May; 11(3):271-6. PubMed ID: 15117331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor necrosis factor genetic polymorphisms and response to antiviral therapy in patients with chronic hepatitis C.
    Rosen HR; McHutchison JG; Conrad AJ; Lentz JJ; Marousek G; Rose SL; Zaman A; Taylor K; Chou S
    Am J Gastroenterol; 2002 Mar; 97(3):714-20. PubMed ID: 11922568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Do polymorphisms of the SDF1 and CCR2b genes modify the course of hepatitis C or HIV/HCV co-infection?].
    Woitas RP; Ahlenstiel G; Iwan A; Rockstroh JK; Brackmann HH; Kupfer B; Matz B; Offergeld R; Sauerbruch T; Spengler U
    Dtsch Med Wochenschr; 2002 Sep; 127(36):1807-12. PubMed ID: 12215924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic polymorphism of low-density lipoprotein receptor did not affect treatment outcome of chronic hepatitis C genotype 3.
    Tanwandee T; Pithukpakorn M; Vipatakul N; Charatcharoenwitthaya P; Chainuvati S; Nimanong S; Prachayakul V; Pongprasobchai S; Manatsathit S; Leelakusolvong S; Pausawasdi N; Kachintorn U; Limwongse C; Udompunturak S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S147-53. PubMed ID: 21721440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A rapid chemokine response of macrophage inflammatory protein (MIP)-1α, MIP-1β and the regulated on activation, normal T expressed and secreted chemokine is associated with a sustained virological response in the treatment of chronic hepatitis C.
    Florholmen J; Kristiansen MG; Steigen SE; Sørbye SW; Paulssen EJ; Kvamme JM; Konopski Z; Gutteberg T; Goll R
    Clin Microbiol Infect; 2011 Feb; 17(2):204-9. PubMed ID: 20219081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of highly active antiretroviral therapy failure with chemokine receptor 5 wild type.
    Bogner JR; Lutz B; Klein HG; Pollerer C; Troendle U; Goebel FD
    HIV Med; 2004 Jul; 5(4):264-72. PubMed ID: 15236615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the clinical usefulness of COBAS AMPLICOR HCV MONITOR assay (ver2.0): Comparison with AMPLICOR HCV MONITOR assay (ver1.0) and HCV core protein level.
    Kawai S; Yokosuka O; Imazeki F; Saisho H; Mizuno C
    J Med Virol; 2002 Nov; 68(3):343-51. PubMed ID: 12226820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RANTES, MCP-1, CCR2, CCR5, CXCR1 and CXCR4 gene polymorphisms are not associated with the outcome of hepatitis B virus infection: results from a large scale single ethnic population.
    Cheong JY; Cho SW; Choi JY; Lee JA; Kim MH; Lee JE; Hahm KB; Kim JH
    J Korean Med Sci; 2007 Jun; 22(3):529-35. PubMed ID: 17596666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic variations in CC chemokine receptors and hypertension.
    Zhang M; Ardlie K; Wacholder S; Welch R; Chanock S; O'Brien TR
    Am J Hypertens; 2006 Jan; 19(1):67-72. PubMed ID: 16461193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C.
    Pawlotsky JM; Pellerin M; Bouvier M; Roudot-Thoraval F; Germanidis G; Bastie A; Darthuy F; Rémiré J; Soussy CJ; Dhumeaux D
    J Med Virol; 1998 Apr; 54(4):256-64. PubMed ID: 9557291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.